nach oben

Erschienen in:

24.06.2019 | Research Article

Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[¹⁸F] F and [¹⁸F]FDG: a Focus on Skeletal Lesions

verfasst von: Ida Sonni, Ryogo Minamimoto, Lucia Baratto, Sanjiv S. Gambhir, Andreas M. Loening, Shreyas S. Vasanawala, Andrei Iagaru

Erschienen in: Molecular Imaging and Biology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study is to prospectively evaluate the performance of sodium ¹⁸F]fluoride (Na[¹⁸F]F)/2-deoxy-2-[¹⁸F]fluoro-D-glucose ([¹⁸F]FDG) simultaneous time-of-flight enabled positron emission tomography (PET)/magnetic resonance imaging (MRI) for the detection of skeletal metastases in selected patients with advanced breast and prostate cancers.

Procedure

The institutional review board approved this HIPAA-compliant protocol. Written informed consent was obtained from each patient. A total of 74 patients (23 women and 51 men with breast and prostate cancer, respectively) referred for standard-of-care whole-body bone scintigraphy (WBBS) were enrolled in this prospective study. All patients underwent a [^99mTc]methyldiphosphonate ([^99mTc]MDP) WBBS followed by Na[¹⁸F]F/[¹⁸F]FDG PET/MRI. Lesions detected by each imaging modality were tabulated and a lesion-based and patient-based analysis was conducted.

Results

On a patient-based analysis, [^99mTc]MDP WBBS identified skeletal lesions in 37 patients and PET/MRI in 45 patients. On a lesion-based analysis, WBBS identified a total of 81 skeletal lesions, whereas PET/MRI identified 140 lesions. Additionally, PET/MRI showed extra-skeletal lesions in 19 patients, including lymph nodes (16), prostate (4) lung (3), and liver (2) lesions.

Conclusions

The ability of Na[¹⁸F]F/[¹⁸F]FDG PET/MRI to identify more skeletal lesions than ^99mTc-MDP WBBS and to additionally identify extra-skeletal disease may be beneficial for patient care and represent an alternative to the single modalities performed separately. Na[¹⁸F]F/[¹⁸F]FDG PET/MRI is a promising approach for evaluation of skeletal and extra-skeletal lesions in a selected population of breast and prostate cancer patients.

Even-Sapir E (2005) Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med 46:1356–1367PubMed

Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176CrossRef

Van den Wyngaert T, Strobel K, Kampen T et al (2016) The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging 43(1723):38

Jacobson AF, Fogelman I (1998) Bone scanning in clinical oncology: does it have a future? Eur J Nucl Med Mol Imaging 25:1219–1223CrossRef

Bombardieri E, Setti L, Kirienko M, Antunovic L, Guglielmo P, Ciocia G (2015) Which metabolic imaging, besides bone scan with 99mTc-phosphonates, for detecting and evaluating bone metastases in prostatic cancer patients? An open discussion. Q J Nucl Med Mol Imaging 59:381–399PubMed

Czernin J, Satyamurthy N, Schiepers C (2010) Molecular mechanisms of bone ¹⁸F-NaF deposition. J Nucl Med 51:1826–1829CrossRef

Even-Sapir E, Metser U, Mishani E et al (2006) The detection of bone metastases in patients with high-risk prostate cancer: ^99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, ¹⁸F-fluoride PET, and ¹⁸F-fluoride PET/CT. J Nucl Med 47:287–297PubMed

Withofs N, Grayet B, Tancredi T, Rorive A, Mella C, Giacomelli F, Mievis F, Aerts J, Waltregny D, Jerusalem G, Hustinx R (2011) ¹⁸F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun 32:168–176CrossRef

Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M, Neumaier B, Träger H, Nüssle K, Reske SN (1999) Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus ¹⁸F PET. J Nucl Med 40:1623–1629PubMed

10.

Iagaru A, Mittra E, Dick DW, Gambhir SS (2012) Prospective evaluation of (99m)Tc MDP scintigraphy, ¹⁸F NaF PET/CT, and ¹⁸F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol 14:252–259CrossRef

11.

Shen CT, Qiu ZL, Han TT, Luo QY (2015) Performance of ¹⁸F-fluoride PET or PET/CT for the detection of bone metastases: a meta-analysis. Clin Nucl Med 40:103–110CrossRef

12.

Fogelman I, Cook G, Israel O, van der Wall H (2005) Positron emission tomography and bone metastases. Semin Nucl Med 35:135–142CrossRef

13.

Jadvar H (2009) Molecular imaging of prostate cancer with ¹⁸F-fluorodeoxyglucose PET. Nat Rev Urol 6:317–323CrossRef

14.

Meirelles GS, Schoder H, Ravizzini GC et al (2010) Prognostic value of baseline [¹⁸F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res 16:6093–6099CrossRef

15.

Iagaru A, Young P, Mittra E, Dick DW, Herfkens R, Gambhir SS (2013) Pilot prospective evaluation of ^99mTc-MDP scintigraphy, ¹⁸F NaF PET/CT, ¹⁸F FDG PET/CT and whole-body MRI for detection of skeletal metastases. Clin Nucl Med 38:e290–e296CrossRef

16.

Iagaru A, Mittra E, Yaghoubi SS, Dick DW, Quon A, Goris ML, Gambhir SS (2009) Novel strategy for a cocktail 18F-fluoride and ¹⁸F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med 50:501–505CrossRef

17.

Lin FI, Rao JE, Mittra ES, Nallapareddy K, Chengapa A, Dick DW, Gambhir SS, Iagaru A (2012) Prospective comparison of combined ¹⁸F-FDG and ¹⁸F-NaF PET/CT vs. ¹⁸F-FDG PET/CT imaging for detection of malignancy. Eur J Nucl Med Mol Imaging 39:262–270CrossRef

18.

Minamimoto R, Loening A, Jamali M, Barkhodari A, Mosci C, Jackson T, Obara P, Taviani V, Gambhir SS, Vasanawala S, Iagaru A (2015) Prospective comparison of ^99mTc-MDP scintigraphy, combined ¹⁸F-NaF and ¹⁸F-FDG PET/CT, and whole-body MRI in patients with breast and prostate Cancer. J Nucl Med 56:1862–1868CrossRef

19.

Sampath SC, Sampath SC, Mosci C, Lutz AM, Willmann JK, Mittra ES, Gambhir SS, Iagaru A (2015) Detection of osseous metastasis by ¹⁸F-NaF/¹⁸F-FDG PET/CT versus CT alone. Clin Nucl Med 40:e173–e177CrossRef

20.

Liu T, Cheng T, Xu W, Yan WL, Liu J, Yang HL (2011) A meta-analysis of ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer. Skelet Radiol 40:523–531CrossRef

21.

Cook GJ, Azad G, Padhani AR (2016) Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology. Clin Transl Imaging 4:439–447CrossRef

22.

Sotoudeh H, Sharma A, Fowler KJ, McConathy J, Dehdashti F (2016) Clinical application of PET/MRI in oncology. J Magn Reson Imaging 44:265–276CrossRef

23.

Mosavi F, Johansson S, Sandberg DT, Turesson I, Sörensen J, Ahlström H (2012) Whole-body diffusion-weighted MRI compared with ¹⁸F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. AJR Am J Roentgenol 199:1114–1120CrossRef

24.

Loening AM, Litwiller DV, Saranathan M, Vasanawala SS (2017) Increased speed and image quality for pelvic single-shot fast spin-Echo imaging with variable refocusing Flip angles and full-Fourier acquisition. Radiology 282:561–568CrossRef

25.

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R (2015) Breast Cancer version 2.2015. J Natl Compr Cancer Netw 13:448–475CrossRef

26.

Groheux D (2018) Role of Fludeoxyglucose in Breast Cancer: Treatment Response. PET Clin 13:395–414CrossRef

27.

Jadvar H (2016) Is There Use for FDG-PET in Prostate Cancer? Semin Nucl Med 46(6):502–506CrossRef

28.

Eiber M, Holzapfel K, Ganter C, Epple K, Metz S, Geinitz H, Kübler H, Gaa J, Rummeny EJ, Beer AJ (2011) Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI. J Magn Reson Imaging 33:1160–1170CrossRef

29.

Stecco A, Trisoglio A, Soligo E, Berardo S, Sukhovei L, Carriero A (2018) Whole-body MRI with diffusion-weighted imaging in bone metastases: a narrative review. Diagnostics (Basel) 8:45CrossRef

30.

Damle NA, Bal C, Bandopadhyaya GP, Kumar L, Kumar P, Malhotra A, Lata S (2013) The role of ¹⁸F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan. Jpn J Radiol 31(4):262–269CrossRef

31.

Araz M, Aras G, Kucuk ON (2015) The role of ¹⁸F-NaF PET/CT in metastatic bone disease. J Bone Oncol 4:92–97CrossRef

32.

Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST (2008) Skeletal PET with ¹⁸F-fluoride: applying new technology to an old tracer. J Nucl Med 49:68–78CrossRef

33.

Iagaru A, Mittra E, Mosci C, Dick DW, Sathekge M, Prakash V, Iyer V, Lapa P, Isidoro J, de Lima JM, Gambhir SS (2013) Combined 18F-fluoride and ¹⁸F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trial. J Nucl Med 54:176–183CrossRef

34.

Grant AM, Deller TW, Khalighi MM, Maramraju SH, Delso G, Levin CS (2016) NEMA NU 2-2012 performance studies for the SiPM-based ToF-PET component of the GE SIGNA PET/MR system. Med Phys 43:2334–2343CrossRef

35.

Segall G, Delbeke D, Stabin M et al (2010) SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med 51:1813Y1820CrossRef

Titel: Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[18F] F and [18F]FDG: a Focus on Skeletal Lesions
verfasst von: Ida Sonni
Ryogo Minamimoto
Lucia Baratto
Sanjiv S. Gambhir
Andreas M. Loening
Shreyas S. Vasanawala
Andrei Iagaru
Publikationsdatum: 24.06.2019
Verlag: Springer International Publishing
Erschienen in: Molecular Imaging and Biology / Ausgabe 2/2020
Print ISSN: 1536-1632
Elektronische ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-019-01392-9

Neu im Fachgebiet Radiologie

23.04.2024 | Pankreaskarzinom | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[¹⁸F] F and [¹⁸F]FDG: a Focus on Skeletal Lesions

Abstract

Purpose

Procedure

Results

Conclusions

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie

Springer Medizin

Abstract

Purpose

Procedure

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Evaluation of a Neurokinin-1 Receptor–Targeted Technetium-99m Conjugate for Neuroendocrine Cancer Imaging

Acute Rodent Tolerability, Toxicity, and Radiation Dosimetry Estimates of the S1P1-Specific Radioligand [11C]CS1P1

Imaging Sigma-1 Receptor (S1R) Expression Using Iodine-124-Labeled 1-(4-Iodophenyl)-3-(2-adamantyl)guanidine ([124I]IPAG)

An Efficient Automated Radiosynthesis and Bioactivity Confirmation of VMAT2 Tracer [18F]FP-(+)-DTBZ

Bifunctional Labeling of Rabbit Mesenchymal Stem Cells for MR Imaging and Fluorescence Microscopy

Quantitative Rodent Brain Receptor Imaging

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie